JP2020518243A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518243A5
JP2020518243A5 JP2019559720A JP2019559720A JP2020518243A5 JP 2020518243 A5 JP2020518243 A5 JP 2020518243A5 JP 2019559720 A JP2019559720 A JP 2019559720A JP 2019559720 A JP2019559720 A JP 2019559720A JP 2020518243 A5 JP2020518243 A5 JP 2020518243A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequences
light chain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019559720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518243A (ja
JP7257967B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030350 external-priority patent/WO2018204303A1/en
Publication of JP2020518243A publication Critical patent/JP2020518243A/ja
Publication of JP2020518243A5 publication Critical patent/JP2020518243A5/ja
Application granted granted Critical
Publication of JP7257967B2 publication Critical patent/JP7257967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019559720A 2017-05-01 2018-05-01 抗pd1抗体試薬に関する方法および組成物 Active JP7257967B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492533P 2017-05-01 2017-05-01
US62/492,533 2017-05-01
PCT/US2018/030350 WO2018204303A1 (en) 2017-05-01 2018-05-01 Methods and compositions relating to anti-pd1 antibody reagents

Publications (3)

Publication Number Publication Date
JP2020518243A JP2020518243A (ja) 2020-06-25
JP2020518243A5 true JP2020518243A5 (https=) 2021-05-13
JP7257967B2 JP7257967B2 (ja) 2023-04-14

Family

ID=64016985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019559720A Active JP7257967B2 (ja) 2017-05-01 2018-05-01 抗pd1抗体試薬に関する方法および組成物

Country Status (6)

Country Link
US (3) US11427636B2 (https=)
EP (1) EP3619230A4 (https=)
JP (1) JP7257967B2 (https=)
CN (1) CN110809582B (https=)
CA (1) CA3060935A1 (https=)
WO (1) WO2018204303A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060935A1 (en) 2017-05-01 2018-11-08 The Children's Medical Center Coporation Methods and compositions relating to anti-pd1 antibody reagents
EP3946377B1 (en) 2019-04-03 2025-12-10 Orega Biotech Combination therapies based on pd1 and il-17b inhibitors
WO2021170750A1 (en) 2020-02-28 2021-09-02 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
US20240294641A1 (en) * 2020-07-13 2024-09-05 The Children's Medical Center Corporation Novel anti-pd1 antibodies for inhibiting t-cell activity
EP4349362A4 (en) * 2021-05-28 2025-05-14 Nippon Kayaku Kabushiki Kaisha COMBINED USE OF UBENIMEX AND IMMUNE CHECKPOINT INHIBITORS
EP4257609A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Combination therapies based on pd-1 inhibitors and sik3 inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US4135884A (en) 1977-08-29 1979-01-23 Shen James T Gamma stick
US4305924A (en) 1979-08-08 1981-12-15 Ventrex Laboratories, Inc. Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system
US4444880A (en) 1982-07-27 1984-04-24 Syva Company Periodate removal of ascorbate interference in dipsticks for immunoassays
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2868900B2 (ja) 1991-01-11 1999-03-10 クイデル コーポレイション ワンステップ側方流非吸収性アッセイ
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6824989B1 (en) 2000-09-01 2004-11-30 Upstate Biotechnology, Inc. Recombinant monoclonal antibody to phosphotyrosine-containing proteins
US6565808B2 (en) 2001-05-18 2003-05-20 Acon Laboratories Line test device and methods of use
US20110009960A1 (en) 2001-11-16 2011-01-13 Allergan, Inc. Prosthetic fabric structure
US6902932B2 (en) 2001-11-16 2005-06-07 Tissue Regeneration, Inc. Helically organized silk fibroin fiber bundles for matrices in tissue engineering
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
MXPA06003686A (es) 2003-10-03 2007-03-01 Brigham & Womens Hospital Ligandos tim-3 y sus metodos.
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
US8172901B2 (en) 2007-03-20 2012-05-08 Allergan, Inc. Prosthetic device and method of manufacturing the same
US8460886B2 (en) 2008-07-04 2013-06-11 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
EP2742953B1 (en) 2011-08-11 2021-09-22 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
PL2904011T3 (pl) * 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
EA034666B1 (ru) * 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
US10034463B2 (en) * 2014-01-24 2018-07-31 Children's Medical Center Corporation High-throughput mouse model for optimizing antibody affinities
US9579673B2 (en) 2014-06-09 2017-02-28 The Procter & Gamble Company Flushing dispensers for delivering a consistent consumer experience
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
HK1254803A1 (zh) * 2015-06-23 2019-07-26 Memorial Sloan Kettering Cancer Center 新型pd -1的免疫调节剂
CN114591433A (zh) * 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
EA201890790A1 (ru) * 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
CA3060935A1 (en) 2017-05-01 2018-11-08 The Children's Medical Center Coporation Methods and compositions relating to anti-pd1 antibody reagents

Similar Documents

Publication Publication Date Title
JP2020518243A5 (https=)
JP2025160458A5 (https=)
JP2019116474A5 (https=)
JP2015172045A5 (https=)
JP2019527553A5 (https=)
JP2021516051A5 (https=)
JP2020533016A5 (https=)
JP2019535670A5 (https=)
JP2008538289A5 (https=)
JP2020534830A5 (https=)
JP2010513539A5 (https=)
JP2021517152A5 (https=)
JPWO2020114480A5 (https=)
RU2019143101A (ru) Новое анти-с-мет антитело и его применение
JP2018522888A5 (https=)
JPWO2021119193A5 (https=)
JP2021530244A5 (https=)
JP2024001073A5 (https=)
JPWO2022256563A5 (https=)
JP2021518415A5 (https=)
CN115461373A (zh) 密蛋白18.2的抗体及其用途
JPWO2019169212A5 (https=)
JPWO2019175885A5 (https=)
JP2020515286A5 (https=)
JPWO2020023644A5 (https=)